Postoperative treatment with docetaxel, cisplatin, and capecitabine (DCX) and chemoradiotherapy (CRT) with capecitabine for resected gastric adenocarcinoma.
| Title | Postoperative treatment with docetaxel, cisplatin, and capecitabine (DCX) and chemoradiotherapy (CRT) with capecitabine for resected gastric adenocarcinoma. |
| Publication Type | Journal Article |
| Year of Publication | 2015 |
| Authors | Saridaki, Z., Lambrodimou G., Kachris S., Makrantonakis P., Boukovinas I., Polyzos A., Anagnostopoulos A., Athanasiadis A., Stoltidis D., Georgoulias V., & Souglakos J. |
| Journal | Am J Clin Oncol |
| Volume | 38 |
| Issue | 1 |
| Pagination | 17-22 |
| Date Published | 2015 Feb |
| ISSN | 1537-453X |
| Keywords | Adenocarcinoma, Adult, Aged, Anemia, Antineoplastic Combined Chemotherapy Protocols, Chemoradiotherapy, Adjuvant, Cisplatin, Deoxycytidine, Feasibility Studies, Female, Fluorouracil, Gastrectomy, Heart Arrest, Humans, Leukopenia, Male, Middle Aged, Neutropenia, Sepsis, Stomach Neoplasms, Taxoids, Treatment Outcome |
| Abstract | INTRODUCTION: We conducted a feasibility study on docetaxel/capecitabine/cisplatin (DCX) with chemoradiotherapy as adjuvant treatment for gastric cancer patients.METHODS: Patients were scheduled to receive 2 cycles of DCX, followed by 50.4 Gy plus capecitabine as radiotherapy, followed by an additional 2-DCX cycles.RESULTS: From the 40 enrolled patients, 26 (65%) completed treatment as per protocol and 14 (35%) discontinued with the treatment (patients' refusal: n=6; adverse events: n=8). There were 2 toxic deaths. Grade >3 toxicity was 12.1% before and 13.3% after chemoradiotherapy. Disease progression was documented in 11 (27.5%) patients.CONCLUSIONS: No further development of this regimen is justified on the basis of poor tolerability in patients. |
| DOI | 10.1097/COC.0b013e3182893f13 |
| Alternate Journal | Am. J. Clin. Oncol. |
| PubMed ID | 23563209 |
